Cambridge Cognition Secures Major Contract for Phase 3 Trials in Adolescent Depression

Cambridge Cognition Holdings ( (GB:COG) ) has shared an update.

Cambridge Cognition has been selected by a major pharmaceutical company to provide digital cognitive and voice assessments for two Phase 3 clinical trials in adolescents with Major Depressive Disorder (MDD). The contracts, valued at approximately £1.2 million, highlight the company’s strategic role in advancing clinical trial methodologies through innovative speech analysis. This partnership is expected to enhance patient monitoring and treatment-response insights, positioning Cambridge Cognition for significant growth in the CNS trials market.

More about Cambridge Cognition Holdings

Cambridge Cognition is a brain health software group specializing in digital health products that advance brain health research and treatment. The company offers four core products: CANTAB® assessments, a flexible eCOA platform, rater training services, and quality assurance tools. These products collectively improve clinical trial outcomes, enable early patient identification, and enhance global efficiency in healthcare and pharmaceuticals.

YTD Price Performance: -4.00%

Average Trading Volume: 30,260

Technical Sentiment Signal: Strong Buy

Current Market Cap: £15.7M

Find detailed analytics on COG stock on TipRanks’ Stock Analysis page.